The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study
Abstract
BACKGROUND: AL amyloidosis is a fatal disease resulting from tissue deposition of amyloid fibrils derived from monoclonal immunoglobulin light chains. Treatment with oral chemotherapy is minimally effective. OBJECTIVE: To test survival and organ response in a large sample of patients treated with high-dose intravenous melphalan (100 to 200 mg/m2) and autologous blood stem-cell transplantation. DESIGN: 8-year longitudinal analysis of clinical effectiveness. SETTING: University-affiliated specialty referral clinic. PATIENTS: 701 consecutive new patients with AL amyloidosis. INTERVENTION: High-dose chemotherapy and autologous stem-cell transplantation for patients who met eligibility requirements based on organ involvement and clinical status. MEASUREMENTS: Survival analysis of all patients evaluated and a detailed analysis of treatment outcome in the subgroup that received high-dose melphalan and stem-cell transplantation. RESULTS: Among 701 patients with AL amyloidosis, 394 (56%) were eligible for high-dose melphalan and stem-cell transplantation; 82 did not proceed with treatment because of patient choice or disease progression. Median survival of the 312 patients who initiated treatment was 4.6 years. A complete hematologic response, defined as no evidence of an underlying plasma cell dyscrasia 1 year after treatment, was achieved in 40% of patients and was associated with prolonged survival. Statistically significant improvements occurred in end-organ disease and were greater in patients with a complete hematologic response. Mortality rate within 100 days of treatment with high-dose melphalan and stem-cell transplantation was 13%; patients with cardiomyopathy had the highest mortality rates. CONCLUSIONS: Treatment of selected patients with AL amyloidosis by using high-dose melphalan and stem-cell transplantation resulted in hematologic remission, improved 5-year survival, and reversal of amyloid-related disease in a substantial proportion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Primary systemic amyloidosis: clinical and laboratory features in 474 cases.
Kyle, R. A., & Ma, G. (1995) · PubMed · Cited by 1,255
Falk, R. H., Comenzo, R. L., & Skinner, M. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709253371306 · Cited by 1,180
Self-citationAMYLOIDOSIS: REVIEW OP 236 CASES
KYLE, K. A., & BAYED, K. D. (1975) · Medicine · doi:10.1097/00005792-197507000-00001 · Cited by 782
Kyle, R. A., Gertz, M. A., Greipp, P. R., Witzig, T. E., Lust, J. A., Lacy, M. Q., & Therneau, T. M. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361702 · Cited by 688
Misdiagnosis of Hereditary Amyloidosis as AL (Primary) Amyloidosis
Lachmann, H. J., Booth, D. R., Booth, S. E., Bybee, A., Gilbertson, J. A., Gillmore, J. D., Pepys, M. B., & Hawkins, P. N. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013354 · Cited by 680
Kyle, R., Linos, A., Beard, C., Linke, R., Gertz, M., O'Fallon, W., & Kurland, L. (1992) · Blood · doi:10.1182/blood.v79.7.1817.1817 · Cited by 657
Amyloidosis (AL). Clinical and laboratory features in 229 cases.
Kyle, R. A., & Greipp, P. R. (1983) · PubMed · Cited by 610
Barlogie, B., Jagannath, S., Vesole, D. H., Naucke, S., Cheson, B., Mattox, S., Bracy, D., Salmon, S., Jacobson, J., Crowley, J., et al. (1997) · Blood · doi:10.1182/blood.v89.3.789 · Cited by 541
Skinner, M., Anderson, J. J., Simms, R. W., Falk, R. H., Wang, M., Libbey, C. A., Jones, L. A., & Cohen, A. S. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)89487-9 · Cited by 370
Self-citation
Cited by
Mehra, M. R., Canter, C. E., Hannan, M. M., Semigran, M. J., Uber, P. A., Baran, D. A., Danziger-Isakov, L., Kirklin, J. K., Kirk, R., Kushwaha, S. S., et al. (2016) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2015.10.023 · Cited by 1,431
Bozkurt, B., Colvin, M., Cook, J., Cooper, L. T., Deswal, A., Fonarow, G. C., Francis, G. S., Lenihan, D., Lewis, E. F., McNamara, D. M., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000455 · Cited by 891
Pepys, M. B. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131243 · Cited by 559
Systemic immunoglobulin light chain amyloidosis
Merlini, G., Dispenzieri, A., Sanchorawala, V., Schönland, S. O., Palladini, G., Hawkins, P. N., & Gertz, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0034-3 · Cited by 552
Self-citationMonoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant
Leung, N., Bridoux, F., Hutchison, C. A., Nasr, S. H., Cockwell, P., Fermand, J.-P., Dispenzieri, A., Song, K. W., & Kyle, R. A. (2012) · Blood · doi:10.1182/blood-2012-07-445304 · Cited by 548
Metadata
- Authors
- Skinner, M., Sanchorawala, V., Seldin, D. C., Dember, L. M., Falk, R. H., Berk, J. L., Anderson, J. J., O'Hara, C., Finn, K. T., Libbey, C. A., Wiesman, J., Quillen, K., Swan, N., & Wright, D. G.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2004-01-20
- Volume
- 140
- Issue
- 2
- Pages
- 85-93
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2109651910
- Cited by
- 618
- References
- 15
- FWCI
- 16.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study. https://app.cochat.ai/papers/10.7326/0003-4819-140-2-200401200-00008
- The paper
- Skinner, M., Sanchorawala, V., Seldin, D. C., Dember, L. M., Falk, R. H., Berk, J. L., Anderson, J. J., O'Hara, C., Finn, K. T., Libbey, C. A., Wiesman, J., Quillen, K., Swan, N., & Wright, D. G. (2004). High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-140-2-200401200-00008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.